NEWS AND RESOURCES

GemPharmatechは、富士フイルム和光純薬株式会社および株式会社特殊免疫研究所と提携し、日本における前臨床マウスモデルとサービスの提供を拡大する。日本全国の販売流通は富士フイルム和光純薬が統括。

このたび、遺伝子改変マウスモデルおよび関連サービスを提供するグローバル企業であるGemPharmatechは、このたび、富士フイルム和光純薬株式会社および株式会社特殊免疫研究所との間で販売代理店契約を締結したことを発表します。本契約により、日本の研究者は、GemPharmatechが提供する革新的なマウスモデルおよび前臨床サービスへのアクセスが大幅に改善されます。

Drug Resistance Models in Mice: Mechanisms, Establishment and Applications

Overcoming Obesity: Challenges Facing Weight Loss Drugs and the Promise of Combination Therapies

Developing Robust Preclinical Evaluation Strategies for T-Cell Engagers (TCEs): Accelerating Development and Reducing Translational Risks

Accelerating TCE Drug Development with Humanized Mouse Models

T-cell engagers (TCEs) are innovative bispecific antibodies designed to bind simultaneously to tumor-associated antigens (TAAs) and the CD3 receptor on T-cells. Several TCE drugs have already been approved, with seven bispecific antibodies targeting indications such as multiple myeloma and diffuse large B-cell lymphoma (DLBCL), focusing on markers like BCMA, GPRC5D, CD20, and CD19. In the realm of solid tumors, two TCE bispecific antibodies have received approval: Tebentafusp (Immunocore, January 2022, targeting CD3×GP100) and Tarlatamab (Amgen, May 2024, targeting CD3×DLL3). The accelerated approval of Tarlatamab has spurred increased interest in TCE bispecific antibodies for drug development in the solid tumor space. However, significant unmet clinical needs remain, especially for TCE bispecific antibodies targeting solid tumors.

To address this gap, GemPharmatech has established a comprehensive preclinical pharmacology and efficacy evaluation platform, offering a range of in vivo tumor models to support the development of TCE-based therapies.

Mouse Models for Studying Anti-PD-1 Resistance

GemPharmatech's Board Appoints Brandy Wilkinson, Ph.D. as its New Chief Executive Officer of GemPharmatech LLC.

GemPharmatech LLC., a leading contract research organization, announced today that its Board of Directors has appointed Dr. Brandy Wilkinson as the Chief Executive Officer of its subsidiary in the United States, effective September 12, 2023.

GemPharmatech Launches New Site and Research Platform in Shanghai Baoshan Base

GemPharmatech and Charles River Laboratories Sign Exclusive Agreement to Distribute Next Generation NCG Portfolio